GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Shiller PE Ratio

Galapagos NV (Galapagos NV) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Shiller PE Ratio Historical Data

The historical data trend for Galapagos NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Shiller PE Ratio Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galapagos NV's Shiller PE Ratio

For the Biotechnology subindustry, Galapagos NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Shiller PE Ratio falls into.



Galapagos NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Galapagos NV's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Galapagos NV's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.489/130.5518*130.5518
=1.489

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 2.541 99.482 3.335
201409 -0.554 99.195 -0.729
201412 -0.419 99.086 -0.552
201503 -0.509 99.423 -0.668
201506 -0.662 100.107 -0.863
201509 -0.808 100.245 -1.052
201512 -1.678 100.572 -2.178
201603 0.880 101.653 1.130
201606 -0.112 102.267 -0.143
201609 -0.595 102.118 -0.761
201612 1.023 102.614 1.302
201703 -0.310 103.972 -0.389
201706 -0.798 103.902 -1.003
201709 -0.870 104.170 -1.090
201712 -0.698 104.804 -0.869
201803 -0.900 105.419 -1.115
201806 -0.491 106.063 -0.604
201809 0.327 106.618 0.400
201812 0.341 107.252 0.415
201903 -1.006 107.876 -1.217
201906 -0.972 107.896 -1.176
201909 6.641 107.470 8.067
201912 -2.411 108.065 -2.913
202003 -0.862 108.550 -1.037
202006 -1.993 108.540 -2.397
202009 -1.472 108.441 -1.772
202012 -1.071 108.511 -1.289
202103 0.167 109.522 0.199
202106 -1.181 110.305 -1.398
202109 -1.165 111.543 -1.364
202112 0.282 114.705 0.321
202203 -0.220 118.620 -0.242
202206 -0.307 120.948 -0.331
202209 0.327 124.120 0.344
202212 -3.347 126.578 -3.452
202303 0.375 126.528 0.387
202306 0.087 125.973 0.090
202309 0.416 127.083 0.427
202312 2.606 128.292 2.652
202403 1.489 130.552 1.489

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (OTCPK:GLPGF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Galapagos NV Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.